Kriya Therapeutics is a next-generation gene therapy company focused on designing and developing transformative gene therapies for highly prevalent serious diseases. With core operations in the Bay Area, California and Research Triangle Park, North Carolina, Kriya is establishing a platform for the development of gene therapies targeting serious chronic diseases affecting millions of patients. The company’s initial pipeline includes multiple programs for the treatment of metabolic diseases including type 1 diabetes, type 2 diabetes, and severe obesity.

Foresite Capital believes the application of gene therapies to more widespread diseases represents a very large and heretofore untapped opportunity.